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Patients with hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT) 
have an extremely poor prognosis.  It is important to select adequate therapeutic options based on reli-
able prognostic factors using imaging studies and clinical data.  Prognostic factors were analyzed in 
patients with HCC with PVTT in the ﬁrst branch or main trunk of the portal vein.  From 2000 to 2007,  
107 consecutive patients with HCC with PVTT in the major portal vein were reviewed,  and diagnostic 
images and clinical characteristics were retrospectively observed.  Thirty-eight possible prognostic 
factors for survival were analyzed by the log-rank test and multivariate analysis using Coxʼs propor-
tional hazards model.  Median overall survival was 14 months following PVTT diagnosis.  Survival 
rates at 6 months,  1,  2,  and 3 years were 72.1ｵ,  52.6ｵ,  32.6ｵ,  and 29.6ｵ,  respectively.  Independent 
prognostic factors for longer survival included: patient age ＜65 years,  Child-Pugh classiﬁcation A/B,  
PVTT treatment,  accumulation of Lipiodol in the PVTT after TACE,  initial radical treatment for 
HCC,  HCC located in a single lobe of the liver,  and no invasion of HCC to the hepatic vein or bile duct.  
Survival was associated with liver function,  tumor extension,  and treatment for HCC and PVTT.
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epatocellular carcinoma (HCC) is one of the 
most common cancers worldwide.  In recent 
years,  the development of imaging techniques has 
facilitated the detection of HCC at early stages 
[1-4].  The introduction of new therapeutic modalities 
such as percutaneous ethanol injection (PEIT),  
radiofrequency ablation (RFA),  and liver transplanta-
tion have provided various options for the treatment of 
HCC,  and have markedly improved the prognosis for 
this disease [5-7].  Despite this marked progress in 
medical science,  the prognosis of advanced HCC 
remains poor,  particularly in patients with tumor 
thrombus in the portal vein (PV).
　 HCC has a high frequency of PV invasion,  which 
is reportedly observed in 11ｵ to 42ｵ of patients 
with HCC [8-11].  Portal vein tumor thrombus 
(PVTT) is a crucial factor that can worsen the prog-
nosis of HCC because it can lead to the wide dissemi-
nation of tumors throughout the liver and cause a 
marked deterioration of hepatic function.  Previous 
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studies have reported that the median survival time of 
patients with PV invasion was 2.7 to 4 months if left 
untreated,  whereas the median survival time in those 
without PV invasion was 24.4 months [12,  13].  
However,  the authors of one previous study found that 
a substantial number of patients with PVTT had an 
extremely poor prognosis (several months),  whereas 
some of these patients survived for several years or 
more [14].
　 Various treatments have been applied to improve 
the short-term prognosis of patients with PV invasion 
of HCC,  but the management of HCC with PVTT in 
the major branches is complicated and controversial.  
No standard treatment has been established for such 
patients.  Tumor thrombus is generally assumed to 
develop during the terminal stage of HCC.  To 
improve outcomes in these patients,  it is important to 
evaluate potential prognostic factors for the elucida-
tion of treatment strategies.  Diagnostic imaging is an 
important tool in the clinical setting to select the 
treatment and to evaluate the eﬃcacy of the treatment 
once delivered.  However,  to our knowledge,  few stud-
ies have evaluated the prognostic factors including 
diagnostic image factors for HCC with PVTT.
　 In this retrospective study,  prognostic factors 
were analyzed in patients with HCC with tumor 
thrombosis in the ﬁrst branch or main trunk of the 
PV.  Imaging characteristics that aﬀected survival 
were evaluated,  and the eﬀects of the location and 
extent of PVTT were evaluated in association with 
long-term outcomes.
Patients and Methods
　 During the 8-year period from January 2000 to 
September 2007,  3,408 patients with HCC were 
admitted to the University of Tokyo Hospital in Japan.  
Of these,  107 (3ｵ) patients were included in this 
study because they had gross PVTT in the ﬁrst 
branch or/and the main trunk of the PV.  Diagnosis of 
HCC was conﬁrmed either by histopathological 
examination or by clinicopathological ﬁndings from 
biopsy specimens,  ultrasonography,  computed tomog-
raphy (CT),  or angiography.  The tumor thrombus 
was diagnosed using contrast-enhanced CT in all 
patients.  On contrast-enhanced CT,  PVTT was 
identiﬁed by the presence of an intraluminal ﬁlling 
defect with generalized enhancement,  intrathrombus 
neovascularity,  accompanying portal venous expan-
sion,  or direct invasion of the PV [15].  Among those 
patients,  14 had PVTT demonstrated by histopathol-
ogy following surgery.
　 CT was performed with multi-detector CT (MDCT) 
systems (LightSpeed QX/I,  LightSpeed Ultra,  GE,  
USA; TOSHIBA Aquilion,  Toshiba,  Japan; Somatom 
Plus 4,  Siemens,  Germany).  In all cases,  non-
enhanced and contrast-enhanced CT (2.5- to 5.0-mm 
slice thickness,  120kVp,  200-400mAs with 5-mm 
axial reconstructions) was performed.  Enhanced 
images were obtained after power injection of 100-
120ml iodinated contrast medium at a rate of 3ml/
sec.  The ensuing average start time for the hepatic 
arterial phase was 30sec.  For the portal venous and 
equilibrium phases,  scans were acquired at 60sec.  
and 180sec,  respectively.  All CT images were evalu-
ated by 2 trained radiologists by consensus.
　 A series of demographic,  biochemical,  and clinical 
data were collected at the time of diagnosis of the 
presence of PVTT and included age,  gender,  pres-
ence of cirrhosis etiology (hepatitis B virus surface 
antigen or hepatitis C virus antibody),  presence of 
liver cirrhosis,  presence of ascites or hepatic enceph-
alopathy,  serum levels of aspartate aminotransferase 
(AST),  alanine aminotransferase (ALT),  total biliru-
bin,  serum albumin,  prothrombin time (ｵ),  platelet 
count,  and serum α-fetoprotein (AFP),  protein induced 
by vitamin K absence or antagonist II (PIVKA-II) 
levels,  the initial therapeutic approach for HCC 
treatment,  and the main PVTT therapy.  The degree 
of liver damage was assessed by Child-Pugh grade.
　 Imaging characteristics of the tumor were evalu-
ated.  For HCC,  2 phases of data were recorded 
which included the initial period and the time PVTT 
was diagnosed.  Characteristics included the number 
of lesions,  gross lesion type,  lobar distribution,  
diameter of the largest nodule,  and presence of extra-
hepatic metastasis.  For the PVTT,  recorded charac-
teristics included location,  type,  maximal diameter of 
the PVTT,  enhancement,  A-P shunt,  and the pres-
ence of hepatic vein or bile duct invasion.  The accu-
mulation of Lipiodol was checked in patients who 
underwent transcatheter arterial chemoembolization 
(TACE).  The eﬀects of location,  treatment for PVTT,  
and the initial HCC therapy were analyzed with 
regard to associations with patient survival.
　 Statistical analysis. Overall,  cumulative sur-
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vival rates were obtained using the Kaplan-Meier 
method.  The starting point for calculating survival 
was the date PVTT was diagnosed,  and the endpoint 
was the date of death.  Patients who were still alive 
through December 31,  2008,  were censored.  Each 
continuous variable was transformed into a binary 
variable divided by a median value.  All possible prog-
nostic factors for survival were analyzed by the log-
rank test.  Independent factors associated with the 
survival rate were assessed using Coxʼs proportional 
hazard regression model,  where signiﬁcant variables 
in a univariate analysis were included in a multivariate 
analysis.  A value of p＜0.05 (two-tailed) was consid-
ered to represent statistical signiﬁcance.  Statistical 
analyses were performed using JMP 9 (SAS Institute,  
Inc.,  Cary,  NC,  USA) software.
Results
　 Patient characteristics. The study population 
included a total of 107 patients (84 males and 23 
females; ratio: 3.7 : 1) with a mean age of 65.3±10.4 
years (range,  27-88 years).  In these patients,  the 
etiology of the background liver disease was hepatitis 
C virus (HCV) in 68 patients (64ｵ,  with 1 patient 
also positive for HBV),  hepatitis B virus (HBV) in 21 
patients (20ｵ),  and non-B non-C hepatitis in 9 
patients (8ｵ).  Non-liver disease was found in only 9 
patients (8ｵ).  A total of 50 patients (47ｵ) were 
classiﬁed with Child-Pugh class A disease,  39 (36ｵ) 
with Child-Pugh class B disease,  and 18 (17ｵ) with 
Child-Pugh class C disease when PVTT was diag-
nosed.  A total of 51 patients (48ｵ) patients had 
PVTT in the ﬁrst branch and 56 (52ｵ) in the main 
trunk of the PV.  The mean of the maximum diameter 
of the intrahepatic HCC was 62.4±38.8mm (range,  
5.5-213mm).  Clinical and imaging characteristics are 
summarized in Table 1 and 2.
　 Survival periods. The average duration of 
follow-up was 18 months (range,  1 to 71 months).  
Forty-six patients were alive,  and 61 patients had 
died (58ｵ) at the end of the follow-up period.  Ten 
patients (9ｵ) died within 30 days.  The causes of 
death were tumor progression in 59 patients,  upper 
gastrointestinal bleeding in 2 patients,  and cardiac 
failure in 1 patient.  The cumulative survival curve for 
all patients is shown in Fig.  1.  Median overall sur-
vival was 14 months following PVTT diagnosis.  
Survival rates at 6 months,  1 year,  2 years,  and 3 
years were 72.1ｵ,  52.6ｵ,  32.6ｵ,  and 29.6ｵ,  
respectively.  Only 1 patient was alive for more than 5 
years of follow-up.
133Prognosis of HCC with PVTTApril 2012
Table 1　 Univariate analysis of clinical characteristics potentially predictive of survival in 107 patients with hepatocellular carcinoma 
complicated by portal vein tumor thrombosis
Variables Category Number Median survivaltime (month)
p-value
(log-rank)
gender female/male 23/84 13.25/14 0.7817　
age ＜65y/ｧ65y 46/61 17.5/10.25 0.0465＊
hepatitis virus positive/negative 89/18 13.75/14.5 0.7752　
ascites absence/presence 69/38 17.5/3.75 0.0018＊
hepatic encephalopathy absence/presence 102/5 14.5/1.5 0.0002＊
AST ＜54/ｧ54 (IU/l) 31/76 20.5/9.5 0.0173＊
ALT ＜54/ｧ54 (IU/l) 63/44 17.5/9.5 0.0625　
Albumin ＜3.5/ｧ3.5 (g/dL) 59/48 9.5/17.5 0.0028＊
total bilirubin ＜2.0/ｧ2.0 (mg/dl) 84/23 15.5/7.5 ＜0.0001＊
prothrombin time ＜70%/ｧ70% 55/52 11.5/17.5 0.1111　
platelet count ＜10/ｧ10 (×104/µl) 29/78  8/17.5 0.0084＊
AFP ＜400/ｧ400ng/ml 57/50 13.75/9.5 0.1264　
PIVKA-Ⅱ ＜40/ｧ40 (mAU/ml) 23/84 16/12.25 0.4292　
PVTT Child-Pugh A, B/C 89/18 19/3 ＜0.0001＊
PVTT treatment treatment/support 92/15 16/4 ＜0.0001＊
HCC initial Child-Pugh A, B/C 99/8 15/3 0.0002＊
HCC initial treatment radical/conservative treatmenta 59/42 20/10 0.0059＊
aradical treatment: surgical resection,  RFA,  PEIT; conservative treatment: TAE,  TAI.
　 Univariate and multivariate analysis.
Possible associations between survival and the clinical 
and imaging variables were evaluated with univariate 
analysis using the Kaplan-Meier method for all 107 
patients.  Fourteen factors were found to have a sig-
niﬁcant negative association with survival in the log-
rank test (Table 1 and 2).  The biochemical and clinical 
variables (11 variables) were: age ＜65 years,  pres-
ence of ascites,  presence of hepatic encephalopathy,  
AST ＜54IU/l,  albumin ｧ3.5g/dl,  total bilirubin 
＜2.0mg/dl,  platelet count ｧ10×104/µl,  Child-
Pugh classiﬁcation grades for the PVTT and initial 
HCC,  HCC initial radical treatment,  and PVTT 
treatment.  The imaging variables (3 variables) were:  
HCC located in a single lobe,  no invasion of HCC to 
hepatic vein or bile duct,  and accumulation of Lipiodol 
in the PVTT after TACE.
　 The remaining variables analyzed were not found 
to have predictive prognostic value in the univariate 
analyses: gender, hepatic virus, ALT, prothrombin time 
ｧ70ｵ, AFP ｧ400ng/ml, PIVKA-II ｧ40mAU/ml;  
for HCC: number of nodules,  size,  extrahepatic 
metastasis; for PVTT: type,  location,  enhancement,  
diameter,  presence of AP-shunt.
　 To evaluate the prognostic factors for the survival 
of HCC patients with PVTT,  we dichotomized the 
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Fig. 1　 Overall survival of 107 patients with hepatocellular carci-
noma and portal vein tumor thrombus (Kaplan-Meier method).
Table 2　 Univariate analysis of CT characteristics potentially predictive of survival in 107 patients with hepatocellular carcinoma com-
plicated by portal vein tumor thrombosis
Variables Category Number Median survivaltime(month)
p-value
(log-rank)
PVTT location main trunk/ﬁrst branch 56/51 11.5/13.5 0.8985　
PVTT type Vp3/Vp4a 46/61 13.5/11.5 0.8519　
PVTT arterial-enhancement yes/no 11/96 13.25/10.5 0.0754　
PVTT venous-hypodense yes/no 11/96 13.25/10.5 0.0754　
PVTT max-diameter ＜16･18mm/ｧ16･18mmb 84/30 13.25/15.5 0.6329　
AP-shunt presence/absence 17/90 11.5/24.5 0.2321　
other invasionc presence/absence 22/85  7.5/17.5 0.0010＊
accumulation of lipiodol presence/absence 39/20 17.5/9.5 0.0082＊
Initial HCC No. of nodules solitary/multiple 31/70 16.5/11.5 0.3444　
Initial HCC size ＜20/ｧ20mm 14/85 16/12.75 0.9678　
＜50/ｧ50mm 62/37 12.5/11.25 0.7661　
Initial HCC location R/L/both lobed 38/15/49 17/9.5/9.75 0.3984　
R, L/both lobe 53/49 17.5/9.75 0.0722　
Initial HCC extrahepatic metastasis presence/absence 12/95 13.75/14.5 0.4615　
HCC No. of nodules solitary/multiple 13/92 17/10.25 0.1386　
HCC size ＜20mm/ｧ20mm  8/97 15/11.5 0.3164　
＜50mm/ｧ50mm 50/55 13.75/10.25 0.6769　
HCC location R, L/both lobe 36/69 17.5/9.5 0.0004＊
HCC extrahepatic metastasis presence/absence 35/72  9.75/13.75 0.4207　
aVp3,  PVTT in ﬁrst-order branches; Vp4,  PVTT in main trunks or/and both ﬁrst branches; bPVTT,  max-diameters were categorized by 
16mm which in the right ﬁrst branches and 18mm which into the left ﬁrst portal brunch or main trunks; cother invasion,  hepatic vein or bile 
duct invasion; dR/L,  right or left lobe.
factors with a signiﬁcant negative association with 
survival listed above and used Coxʼs proportional 
hazard model for multivariate analysis (Table 3).  The 
analysis revealed that the following variables were 
independent predictors for longer survival: patient 
age ＜65 years,  PVTT Child-Pugh classiﬁcation grade 
A/B,  PVTT treatment,  accumulation of Lipiodol in 
PVTT after TACE,  initial radical treatment for 
HCC,  HCC located in a single lobe,  and no invasion 
of the hepatic vein or bile duct.  A platelet count of 
ｧ10×104/µl was not identiﬁed to be a prognostic 
factor by Coxʼs proportional hazard model.
　 The eﬀect of the extent of the PVTT on survival 
was evaluated in terms of association with the curative 
strategy for PVTT and the initial treatment for HCC 
(Tables 4-6).  The evaluation showed a non-signiﬁcant 
negative association with invasion of the major 
branches of the portal trunk (Fig.  2).  Treatment for 
PVTT was associated with better survival than sup-
portive care alone (Fig.  3).  Especially,  surgical 
resection was seen to be associated with better out-
comes (Fig.  4).  Radiotherapy also had a positive 
association with outcome (Fig.  5).  Concerning HCC 
initial treatments and prognosis,  radical therapies 
were better than conservative treatment,  hepatectomy 
was better than TACE/transcatheter arterial infusion 
135Prognosis of HCC with PVTTApril 2012
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0 10 20 30 40 50 60 70
cu
m
ul
at
iv
e 
su
rv
iv
al
 ra
te
survival time (months)
ﬁrst branch
main trunk
Fig. 2　 Comparison of survival rates between patients with PVTT 
located at the main trunk of the portal vein and at the ﬁrst branch of 
the portal vein.  There was no signiﬁcant diﬀerence (p＝0.8985;  
log-rank test).
Table 3　 Multivariate analysis of prognostic factors by the Cox proportional hazard model
Factor Category Hazard radio 95％CI p-value
age ＜65y/ｧ65y 1.3734 0.9997-1.8868 0.0471＊
AST ＜54UI/ｧ54UI 0.9537 0.2563-3.5487 0.0923　
PLT ｧ10/＜10 (×104/µl) 1.1199 0.8375-1.4975 0.4475　
PVTT Child-Pugh A, B/C 1.3609 1.0065-1.8404 0.0444＊
PVTT treatment treatment/support 1.6219 1.1023-2.3865 0.0183＊
HCC initial Child-Pugh A, B/C 0.8316 0.1547-4.4707 0.1825　
HCC initial treatment radical/conservative treatmenta 1.8874 1.3582-2.6229 ＜0.0001＊
accumulation of lipiodol presence/absence 1.3508 0.9922-1.8391 0.0490＊
other invasion absence/presence 1.5269 1.1091-2.1022 0.0145＊
HCC location R, L/both lobe 1.7257 1.1937-2.4947 0.0024＊
aradical treatment: surgery resection,  RFA,  PEIT; conservative treatment: TAE,  TAI.
Table 4　 Survival comparison according to location of the portal vein tumor thrombosis
Category Number Median survivaltime (month)
p-value
(log-rank)
R/L/M/B/a 23/23/46/15 14/14/13.5/10 0.8634
main trunk/ﬁrst branch 51/56 14/12 0.8985
Vp3/Vp4b 46/61 14/12 0.8519
R/L 23/23 14/14 0.5389
M/B 46/15 13.5/10 0.5303
aR,  right ﬁrst branch; L,  left ﬁrst branch; M,  main trunk; B,  both ﬁrst branch.
bVp3,  PVTT in ﬁrst-order branches; Vp4,  PVTT in main trunks or/and both ﬁrst branches.
(TAI),  and TACE/TAI was better than supportive 
care.
Discussion
　 HCC patients with PVTT have an extremely poor 
prognosis.  It is important to evaluate potential prog-
nostic factors for the elucidation of treatment strate-
gies.  Even after concomitant partial liver resection 
and thrombectomy,  the postoperative 5-year survival 
rate has been reported to be only 10-30ｵ [14].  The 
most eﬀective treatment strategy for HCC with 
PVTT remains to be established.  It is important to 
choose adequate therapeutics based on reliable prog-
nostic factors,  including both imaging studies and 
clinical data for such patients.
　 In this study,  the univariate analysis revealed sig-
niﬁcant diﬀerences for 14 of 33 factors; multivariate 
analysis found that 4 clinical factors (age,  PVTT 
Child-Pugh classiﬁcation grade,  radical vs.  conserva-
tive initial HCC treatment,  PVTT treatment vs.  
supportive care) and 3 imaging factors (intrahepatic 
extent of HCC,  hepatic vein or bile duct invasion,  
accumulation of Lipiodol in the PVTT after TACE) 
were independent prognostic factors for overall sur-
vival.
　 Age ＜65 years was the only signiﬁcant prognostic 
factor in the patient background category in this study.  
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Table 6　 Survival comparison according to the initial treatment for hepatocellular carcinoma
Category Number Median survivaltime (month)
p-value
(log-rank)
OPE/RFA/PEIT/TACE/TAI/supporta 30/18/11/29/13/6 21/20/19/10/6/1.5 ＜0.0001＊
radical/conservative treatmentb 59/42 20/10 0.0059＊
OPE/RFA 30/18 21/20 0.8163　
OPE/PEIT 30/11 21/19 0.8158　
OPE/TACE 30/29 21/10 0.0247＊
OPE/TAI 30/13 21/6 0.0265＊
RFA/PEIT 18/11 20/19 0.8329　
RFA/TACE 18/29 20/10 0.1673　
PEIT/TACE 11/29 19/10 0.1536　
TACE/TAI 29/13 10/6 0.4134　
TAI/support 13/6  6/1.5 0.0060＊
aOPE,  surgical resection; PEIT,  percutaneous alcoholinjection; RFA,  radiofrequency ablation; TACE,  transcatheter arterialchemoembo-
lisation; TAI,  transcatheter arterial infusion.
bradical treatment,  surgical resection,  RFA; PEIT conservative treatment,  TAE,  TAI.
Table 5　 Survival comparison according to the main treatment for portal vein tumor thrombosis
Category Number Median survivaltime (month)
p-value
(log-rank)
OPE/RT/TACE/TAI/supporta 14/18/35/25/15 44/14/15/10/4 ＜0.0001＊
treatment/support 92/15 16/4 ＜0.0001＊
OPE/RT 14/18 44/14 0.0699　
OPE/TACE 14/35 44/15 0.0825　
OPE/TAI 14/25 44/10 0.0380＊
OPE/support 14/15 44/4 ＜0.0001＊
RT/TACE 18/35 14/15 0.9610　
RT/TAI 18/25 14/10 0.3940　
RT/support 18/15 14/4 0.0003＊
TACE/TAI 35/25 15/10 0.4423　
TACE/support 35/15 15/4 ＜0.0001＊
TAI/support 25/15 10/4 0.0341＊
aOPE,  surgical resection; RT,  radiotherapy; TACE,  transcatheter arterialchemoembolisation; TAI,  transcatheter arterial infusion.
The risk of HCC is known to be age dependent,  but 
the inﬂuence of age on prognosis is controversial.  Age 
was not found to be a prognostic factor in some previ-
ous studies performed on HCC patients with PVTT 
[16,  17].  However,  the present data may conform to 
the generally accepted theory that younger patients 
need to be treated in order to gain longer survival,  
and that these patients should be treated with a posi-
tive,  radical approach if possible.
　 Among measurements of liver function,  factors 
signiﬁcantly associated with prognosis were AST,  
albumin,  and total bilirubin.  The presence of ascites 
and hepatic encephalopathy were also associated with 
signiﬁcant diﬀerences in survival by univariate analy-
sis.  Except for the level of AST,  other parameters 
are used in the Child-Pugh classiﬁcation system.  
Child-Pugh grading was an independent factor with a 
signiﬁcant inﬂuence on overall survival based on both 
univariate and multivariate analyses.  Poor overall 
survival rates in the present study were strongly 
associated with liver function.  In patients with Child-
Pugh grade C,  the survival rate at 6 months was 
32.4ｵ,  and no patients survived longer than 10 
months.  There was no signiﬁcant diﬀerence in the 
survival of Child-Pugh grade C patients between the 
treated and the untreated groups.  Similar results have 
been previously reported [18].  Therefore,  it might 
be that Child-Pugh class C patients with PVTT 
should not be subjected to active treatment.
　 Applied treatment was another major factor pre-
dictive of survival.  Both univariate and Coxʼs multi-
variate analyses showed that the strategy of treatment 
for HCC and PVTT were positive prognostic factors.  
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Fig. 3　 Comparison of survival rates between treatment and sup-
portive care alone for HCC patients with PVTT.  A signiﬁcant diﬀer-
ence in survival rate was observed (p＜0.0001; log-rank test).
Ａ Ｂ
Ｃ
Fig. 4　 A 57-year-old man. Survival time was 41 months.  CT ﬁndings after combination therapy of preoperative TACE and hepatic 
resection.  A,  Portal-dominant phase dynamic CT showed a solitary HCC in segment 8 (arrowhead) with portal vein tumor thrombus in the 
right ﬁrst branch (arrow); B,  On the plain CT taken 3 weeks after TACE,  an iodized oil (Lipiodol) accumulated in the nodule of the HCC 
(arrowhead) and portal vein tumor thrombus located at the right ﬁrst branch (arrow); C,  Arterial-dominant phase dynamic CT 8 weeks after 
hepatic resection.  HCC and tumor thrombus disappeared,  and the portal blood ﬂow in the left liver was normal (arrow).
Curative initial treatment for HCC was an indepen-
dent prognostic factor.  The cumulative survival rate 
for locoregional curative treatments for HCC (includ-
ing liver resection,  PEIT,  and RFA) were better than 
conservative treatments (including TACE,  TAI).  The 
survival rates at 6,  12,  and 24 months for locore-
gional curative treatments were 82.3ｵ,  69.9ｵ,  and 
45.6ｵ,  respectively,  and for conservative treatments 
were 64.9ｵ,  31.9ｵ,  and 17.1ｵ,  respectively.  The 
present cases also had large diﬀerences in survival 
between the treated and untreated groups (with sup-
portive care alone).  The median survival time was 16 
months for the treatment group,  whereas the median 
survival time for the supportive care group was 4 
months.  The survival rates at 6,  12,  and 24 months 
for the treated group were 76.6ｵ,  60.5ｵ,  and 37.5ｵ,  
respectively,  and for the untreated group were 36.4ｵ,  
0ｵ,  and 0ｵ,  respectively.
　 Among the treatment strategies,  surgical resection 
was the most eﬀective therapy.  Therefore,  surgical 
resection may be regarded as the only potentially 
curative treatment for HCC with PVTT.  Hepatic 
resection is usually not suitable for patients who have 
HCC with a tumor thrombus in the main trunk or 
major branches of the portal vein.  Patients need to 
have good liver function and performance status for 
surgical treatment.  Moreover,  the volume of resected 
liver tends to be large,  resulting in a high frequency 
of postoperative complications and tumor recurrence 
[19,  20].  In the present study only a few (13ｵ,  
14/107) patients received resection surgery.  The 
survival rates at 1,  2,  3,  and 5 years for surgical 
treatments were 83.9ｵ,  73.4ｵ,  58.7ｵ,  and 0ｵ,  
respectively.
　 Several nonsurgical modalities can be used for 
patients who have HCC with PVTT,  such as TACE,  
TAI (including continuous hepatic arterial infusion 
chemotherapy,  CHAIC),  and radiotherapy (RT).  TACE 
is usually contraindicated in patients with portal 
obstruction because of the high risk of hepatic insuf-
ﬁciency.  Recently,  Lee et al.  reported that TACE 
can be safe for patients who have HCC with PVTT if 
suﬃcient collateral circulation around the portal trunk 
were established [21].  In the present retrospective 
series,  59 patients received TACE,  and the accumu-
lation of iodized oil (Lipiodol) not only in HCC nodules 
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Fig. 5　 An 85-year-old woman.  Survival time was 27 months.  CT ﬁndings after radiation therapy.  A,  B,  Arterial-dominant phase and 
portal-dominant phase dynamic CT show a HCC in segment 2 (arrowhead) with portal vein tumor thrombus in the left ﬁrst branch (arrow);  
C,  Dynamic CT 7 weeks after radiotherapy shows a reduction in the size of the tumor thrombus and improved portal blood ﬂow in the left 
liver (arrow).
but also in PVTT was seen in the vast majority of 
patients (66ｵ,  39/59).  Similar results have been 
reported by Minagawa et al.,  that necrosis of the 
PVTT was detected by pathologic examination [22].  
It seems reasonable to suppose that TACE can impair 
the rapid growth of PVTT.
　 In recent years,  RT has been reported to be used 
for HCC patients with major PV invasion.  RT has 
limited beneﬁt for patients with HCC owing to the low 
tolerance of the whole liver to radiation [23,  24].  
Combined treatment for liver tumors consisting of 3-D 
CRT for PVTT and TACE was reported to have a 
response rate from 40ｵ to 60ｵ and a median survival 
time from 7 to 10 months [25,  26].  In the present 
study,  18 patients received RT in the form of 3-D 
CRT.  The mean radiation dose was 52Gy (range 
10-60Gy) delivered a mean of 26 times (range 5-30 
times),  depending on the tolerance and the functional 
reserve of the liver.  A response was observed in 15 
of 18 patients; the response rate was 83ｵ,  and the 
median survival time was 14 months.
　 Because the present study design was retrospec-
tive,  tumor characteristics were diﬀerent between the 
treatment groups.  Thus,  the exact diﬀerence in sur-
vival between these groups could not be compared.  
Therapeutic procedures for patients who have HCC 
with PVTT are limited and controversial,  and new 
treatment strategies are required.
　 With regard to imaging characteristics,  the tumor 
size,  number,  and extent are well known to be prog-
nostic factors after treatment in patients with HCC 
[27].  The present study recorded two-phase data for 
HCC,  including the initial period and the time PVTT 
was diagnosed.  Of those factors,  only the extent of 
HCC was seen to be a signiﬁcant and independent 
determinant of survival.  The present study had many 
patients with multiple HCC; 69 patients (64ｵ) had 
HCC that had spread to both lobes.  On the other 
hand,  in 22 patients only the right lobe was aﬀected,  
and in 14 patients only the left lobe was aﬀected.  The 
median survival times of these 3 groups were 9.5 
months,  17 months,  and 15.5 months,  respectively.  
There were no signiﬁcant diﬀerences in survival 
between the groups with HCC distributed in the right 
or left lobe,  but there were signiﬁcant diﬀerences in 
survival between patients with HCC in both lobes 
compared with patients with HCC in only 1 lobe (p＝
0.0004).  For advanced HCC,  prognosis should be 
even worse if the HCC has spread to both lobes.
　 HCC often involves the intrahepatic portal vein,  
but sometimes hepatic venous or bile duct invasion is 
present.  Although the rate of hepatic venous invasion 
is only 9ｵ [10],  and it is a less common ﬁnding 
compared to portal venous invasion,  it is thought to be 
an important prognostic factor regulating recurrence 
and survival after surgical resection in HCC patients 
[28,  29].  It was reported that the 5-year survival 
rate after hepatectomy was 54.1ｵ in the absence of 
hepatic venous invasion,  but it was 33.7ｵ in the pres-
ence of hepatic venous invasion [10].  In the present 
data,  12 patients (11ｵ) were found to have hepatic 
venous invasion when the PVTT presented (10 of those 
patients had inferior vena cava involvement).  The 
median survival time for those patients was 5.0 
months,  and the survival rates at 1,  2,  and 3 years 
were 30.9ｵ,  15.4ｵ,  and 0ｵ,  respectively.
　 Bile duct invasion occurs even less frequently than 
does hepatic venous invasion,  with a rate of only 4ｵ 
[10].  Tumor invasion into the bile duct sometimes 
causes obstructive jaundice.  Ikenaga et al.  reported 
that the median survival time after hepatectomy was 
56.1 months for patients without bile duct invasion,  
but it was 11.4 months for patients with bile duct 
invasion [30].  In the present study,  10 patients (9ｵ) 
were found to have bile duct invasion simultaneously 
present with PVTT.  For those patients the median 
survival time was 7 months,  and the survival rate at 1 
year was 23ｵ and at 2 years was 0ｵ.
　 According to the present data,  other vascular inva-
sion along with portal vein invasion,  including hepatic 
vein,  IVC (inferior vena cava),  and bile duct invasion 
was 20.6ｵ (22/107 patients) overall.  There was a 
signiﬁcant diﬀerence in the median survival time 
between patients with and without other vascular inva-
sion (p＝0.001),  7.5 months and 17.5 months,  respec-
tively.  Other vascular invasion along with portal vein 
invasion was an independent prognostic factor and 
therefore should receive full attention during diagnos-
tic imaging.
　 As reported above,  signiﬁcant factors for progno-
sis of HCC with PVTT were evaluated.  Some factors 
that have been thought to aﬀect prognosis did not 
appear to be associated with signiﬁcant diﬀerences in 
survival in the present study.  For example,  high lev-
els of the serum tumor markers AFP and PIVKA-II 
were believed to predict a worse prognosis.  Inves-
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tigators of the Cancer of the Liver Italian Program 
also reported that AFP was an independent prognostic 
factor [31].  However,  we couldnʼt found signiﬁcant 
association between levels of AFP or PIVKA-II with 
survival in the present study.  It is possible that 
because only HCC patients with PVTT were enrolled 
in our study,  the population was diﬀered from that of 
the previous studies that enrolled patients with HCC 
with or without PVTT.
　 Hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infection are the 2 most important etiologic 
agents of HCC.  The long-term survival of patients 
with HCC who have diﬀerent hepatitis viral infections 
has been controversial [32-34].  In the present study,  
there was no signiﬁcant diﬀerence in survival strati-
ﬁed by either hepatitis B or hepatitis C serology.
　 Extrahepatic metastases have been reported as a 
poor prognostic factor for HCC patients.  The median 
survival period of patients with HCC with extrahe-
patic metastases was just 5 to 8 months [35,  36].  
But in the present study,  extrahepatic metastasis,  to 
either distant organs or lymph nodes,  was not associ-
ated with prognosis.  We suspect this is because the 
patients in this study were limited to those with 
advanced HCC complicated with PVTT at the major 
portal vein,  and thus our study population was diﬀer-
ent from those of previous studies.
　 In conclusion,  prognostic factors were analyzed for 
HCC patients with tumor thrombosis in the major 
portal vein.  Survival was associated with variables 
reﬂecting liver function,  as assessed by Child-Pugh 
classiﬁcation,  by treatments for HCC and PVTT,  and 
also by tumor extension.  All treatments inﬂuenced 
patient outcomes,  although only in the advanced 
stages.  The results of treatments for patients with 
this disease remain unsatisfactory.  Further preven-
tion,  early diagnosis,  and development of new treat-
ment strategies are required for such patients.
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